Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14400453 | 1.00 | HPGD (0.70) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL1703978 | 0.85 | RAB9A (0.68) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL11642079 | 0.84 | CYP1A2 (0.73) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL31435389 | 0.83 | RAB9A (0.61) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL420721 | 0.83 | RAB9A (0.61) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL1008033 | 0.83 | RAB9A (0.54) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL23997341 | 0.82 | HPGD (0.51) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL18605307 | 0.82 | MAPT (0.54) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL30336857 | 0.82 | HPGD (0.51) | HPGDKMT2AMEN1POLBRAB9A | |
| SCHEMBL30336895 | 0.82 | MAPT (0.54) | HPGDKMT2AMEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | HPGD 831/4885KMT2A 3013/4885MEN1 1034/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | HPGD 831/4885KMT2A 3013/4885MEN1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.